Page last updated: 2024-08-24

adenosine and Stroke

adenosine has been researched along with Stroke in 99 studies

Research

Studies (99)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (15.15)29.6817
2010's76 (76.77)24.3611
2020's8 (8.08)2.80

Authors

AuthorsStudies
Heleä, JJ; Järvelä, KM; Laurikka, JO; Mattila, MS; Nikus, KC; Rantanen, MJ; Rinne, TT; Siltanen, JAA1
Chen, YS; Hsieh, ST; Wang, YC1
Feng, J; Hao, M; Jiang, C; Li, Q; Ling, Y; Liu, F; Shang, X; Wang, B; Xiao, Z; Zhao, H; Zhao, N1
Bai, Y; Bian, L; Chao, J; Gu, X; Han, B; Li, B; Li, L; Liu, C; Liu, X; Shen, L; Tang, Y; Wang, J; Wang, Y; Xi, W; Xie, J; Yang, L; Yao, H; Yu, X; Zhang, Y; Zhou, Z1
Chen, Y; Han, W; Tian, Y; Wang, S; Zhang, E1
Borea, PA; Casetta, I; Gessi, S; Laudisi, M; Merighi, S; Pasquini, S; Varani, K; Vincenzi, F1
Boland, P; Chong, AY; Di Santo, P; Froeschl, M; Gaudet, C; Hibbert, B; Joseph, J; Jung, RG; Labinaz, A; Le May, M; Marbach, J; Moreland, R; Motazedian, P; Parlow, S; Promislow, S; Ramirez, FD; Russo, JJ; Simard, T; So, D1
Angiolillo, D; Birnbaum, Y; Khawaja, M; Kherallah, RY; Olson, M1
Cao, Y; Chen, G; Chen, W; Li, H; Li, J; Li, X; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wang, Z; Wu, J; Xu, Y; Zhang, G; Zhao, X1
Carr, K; Ghamasaee, P; Grandhi, R; Johnson, J1
Hua, YH; Li, JN; Liu, C; Liu, J; Song, L; Tan, Y; Wu, Y; Yan, HB; Yang, YM; Zhao, HJ; Zhou, P1
Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L1
Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL1
Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL1
Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL2
Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, DJ; Cohen, M; Li, H; Magnuson, EA; Sabatine, MS; Shafiq, A; Steg, PG; Storey, RF; Vilain, K; Wang, K1
Alexopoulos, D; Goudevenos, J; Hamilos, M; Kanakakis, J; Kochiadakis, G; Lekakis, J; Petousis, S; Sitafidis, G; Skalidis, E; Vardas, PE; Vavouranakis, M; Xanthopoulou, I1
Al-Salama, ZT; Keam, SJ; Keating, GM1
He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z1
Baumgartner, I; Berger, JS; Björck, M; Blomster, JI; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Wojdyla, DM1
Abe, T; Elkordy, A; Mishima, E; Niizuma, K; Rashad, S; Shehabeldeen, H; Tominaga, T1
Lei, SF; Mo, XB; Zhang, H; Zhang, YH1
Himi, N; Itano, T; Maruyama, T; Miyamoto, O; Nakamura, E; Nakamura, T; Narita, K; Okabe, N; Sakakibara, N; Tsukamoto, I1
Becker, RC; Cannon, CP; Harrington, RA; James, SK; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L2
DiNicolantonio, JJ; Serebruany, VL1
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G1
Aylward, P; Brandrup-Wognsen, G; Brilakis, ES; Claeys, MJ; Cools, F; Cornel, JH; Held, C; Himmelmann, A; James, SK; Lewis, BS; Meier, B; Stevens, SR; Wallentin, L; Weaver, D1
Bansilal, S; Bonaca, MP; Sabatine, MS1
Hartmark-Hill, JR; Tsang, K1
Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M1
Angiolillo, DJ; Antoniucci, D; Bernlochner, I; Hamm, C; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Neumann, FJ; Richardt, G; Ruf, J; Schömig, G; Schühlen, H; Schulz, S; Schunkert, H; von Merzljak, B1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ1
Abbracchio, MP; Cimino, M; Enerbäck, M; Fumagalli, M; Gelosa, P; Lecca, D; Nikookhesal, E; Pignieri, A; Sironi, L; Tremoli, E; Verderio, C; Wypych, D1
Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D1
Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM1
Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E1
Lindquist, BE; Shuttleworth, CW1
Gaussem, P; Godier, A; Taylor, G1
Ducruet, AF; Faraji, AH; Weiner, GM1
Burnstock, G1
Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ1
Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY1
Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P1
Angiolillo, DJ; Bansilal, S; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Im, K; Murphy, SA; Sabatine, MS; Steg, PG; Storey, RF1
Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF1
Biby, S; Campbell, BC; Lo, KY; Sethi, P1
Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS2
Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C1
Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD1
Anstrom, K; Bhandary, DD; Cannon, CP; Choudhry, NK; Cohen, DJ; Davidson-Ray, LD; Doll, JA; Fonarow, GC; Henry, TD; Khan, N; Peterson, ED; Wang, TY1
Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D1
Ding, Y; Geng, X; Khan, H; Liu, K; Zhang, J1
Chung, SC; Denaxas, S; Emmas, C; Hemingway, H; Moayyeri, A; Pasea, L; Pujades-Rodriguez, M; Rapsomaniki, E; Shah, AD; Stogiannis, D; Timmis, A1
Aylward, PE; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dalby, AJ; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Kontny, F; Kuder, J; Magnani, G; Medina, FA; Oude Ophuis, T; Sabatine, MS; Špinar, J; Steg, PG; Storey, R; Theroux, P1
Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M1
Priglinger, ML1
Holmes, D1
Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF1
Attmann, T; Beyersdorf, F; Boening, A; Cremer, J; Danner, BC; de Waha, A; Fischlein, T; Goerlach, G; Hambrecht, R; Hamm, C; Hammel, D; Joost, A; Kastrati, A; Knosalla, C; Koch-Buettner, K; Lange, R; Laufer, G; Misfeld, M; Mohr, FW; Oberhoffer, M; Putman, LM; Radke, PW; Sandner, S; Schmoeckel, M; Schöndube, FA; Schönrath, F; Schulz, R; Schunkert, H; Siepe, M; Sievers, HH; von Scheidt, M; Walther, T; Zeymer, U; Ziegelhöffer, T1
Alexopoulos, D; Lekakis, J; Moulias, A; Xanthopoulou, I1
Avgerinos, E; Bakoyiannis, C; Moris, D1
Johnston, SC; Wang, Y1
Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L1
Collet, JP; Montalescot, G1
Atar, D; Serebruany, VL2
Cattaneo, M1
Komai, M; Koseki, T; Shirakawa, H; Sugita, Y1
Easton, JD1
Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM1
Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM1
Calvi, V; Capodanno, D; Tamburino, C1
Angiolillo, DJ; Cannon, CP; Cantor, WJ; Clare, R; Goodman, SG; Harrington, RA; Husted, S; James, SK; Kilhamn, J; Mahaffey, KW; Nicolau, JC; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L1
Serebruany, VL2
Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF1
Verheugt, FW1
Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L1
Anderson, RD; Azarbal, B; Handberg, E; Johnson, BD; Kar, S; Kelsey, SF; Kothawade, K; Lerman, A; Mehta, PK; Merz, CN; Pepine, CJ; Petersen, J; Samuels, B; Sharaf, B; Shaw, L; Shufelt, C; Sopko, G; Wei, J1
Ambrosio, G; Ferguson, TB; Harrington, RA; Koglin, J; Lira, A; Newman, MF; Nussmeier, NA; Pearl, RG; Pitt, B; Reece, TL; Wechsler, AS; Weisel, RD; White, JA1
Fort, JG; Plachetka, JR1
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A1
Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L1
Bernhardt, P; Buckert, D; Dewes, P; Rottbauer, W; Walcher, T1
Danton, G; Dietric, WD; Prado, R; Watson, BD1
Schaper, W1
Kennedy, TP; Vinten-Johansen, J1
Boison, D1
Capone, C; Girouard, H; Iadecola, C; Lessard, A; Milner, TA1
Setarehbadi, R; Sheikh, N; Tavilani, H; Vaisi-raygani, A1
Fricker, J1
Di Perri, T; Guideri, F; Laghi Pasini, F; Parenti, G; Petersen, C; Picano, E; Varga, A1
Bergmann, SR1
von Lubitz, DK1
Lin, RC; Simpson, KL; Von Lubitz, DK1
Kambayashi Ji, J; Liu, Y; Shakur, Y; Yoshitake, M1

Reviews

20 review(s) available for adenosine and Stroke

ArticleYear
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
    Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:4

    Topics: Adenosine; Cilostazol; Humans; Intermittent Claudication; Platelet Aggregation Inhibitors; Stroke; Tetrazoles

2022
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
    Stroke, 2017, Volume: 48, Issue:9

    Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Failure

2017
Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.
    Drugs, 2017, Volume: 77, Issue:18

    Topics: Adenosine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor

2017
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2013
Ticagrelor for acute coronary syndromes.
    Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine

2013
Ticagrelor (Brilinta) for secondary prevention of thrombotic events following acute coronary syndrome.
    American family physician, 2013, Dec-15, Volume: 88, Issue:12

    Topics: Acute Coronary Syndrome; Adenosine; Drug Administration Schedule; Drug Costs; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; United States

2013
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
    Stroke, 2014, Volume: 45, Issue:2

    Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases

2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Atherosclerosis, 2014, Volume: 233, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine

2014
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
    Annals of medicine, 2014, Volume: 46, Issue:7

    Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine

2014
An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.
    Neuropharmacology, 2016, Volume: 104

    Topics: Adenosine; Animals; Brain; Brain Ischemia; Humans; Nerve Regeneration; Neural Stem Cells; Neurodegenerative Diseases; Neurons; Purines; Pyrimidines; Receptors, Purinergic; Receptors, Purinergic P2X; Receptors, Purinergic P2Y; Signal Transduction; Stroke

2016
Pharmacological hypothermia: a potential for future stroke therapy?
    Neurological research, 2016, Volume: 38, Issue:6

    Topics: Adenine Nucleotides; Adenosine; Animals; Cannabinoids; Humans; Hypothermia; Hypothermia, Induced; Neuroprotective Agents; Neurotensin; Receptors, Dopamine; Receptors, Opioid; Stroke; Thyroxine; TRPV Cation Channels

2016
Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?
    Journal of the American College of Cardiology, 2016, 09-13, Volume: 68, Issue:11

    Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Time Factors

2016
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
    Current atherosclerosis reports, 2011, Volume: 13, Issue:4

    Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine

2011
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Endothelium-targeted pharmacotherapeutics for the treatment of stroke.
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:6

    Topics: Adenosine; Animals; Brain Ischemia; Clinical Trials as Topic; Disease Models, Animal; Endothelium, Vascular; Free Radical Scavengers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase Inhibitors; Serotonin Antagonists; Stroke; Vasodilator Agents

2002
Dipyridamole, an underestimated vascular protective drug.
    Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:5

    Topics: Adenosine; Angina Pectoris; Animals; Atherosclerosis; Coronary Circulation; Coronary Vessels; Dipyridamole; Heart; Humans; Myocardium; Nucleoside Transport Proteins; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Vasodilator Agents

2005
A review of the clinical use of anti-inflammatory therapies for reperfusion injury in myocardial infarction and stroke: where do we go from here?
    Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:3

    Topics: Adenosine; Anti-Inflammatory Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; Stroke; Vasodilator Agents

2006
Adenosine kinase, epilepsy and stroke: mechanisms and therapies.
    Trends in pharmacological sciences, 2006, Volume: 27, Issue:12

    Topics: Adenosine; Adenosine Kinase; Animals; Brain; Drug Delivery Systems; Enzyme Inhibitors; Epilepsy; Humans; Stroke

2006
Adenosine in the treatment of stroke: yes, maybe, or absolutely not?
    Expert opinion on investigational drugs, 2001, Volume: 10, Issue:4

    Topics: Adenosine; Brain Ischemia; Humans; Phosphatidylinositols; Receptors, Purinergic P1; Stroke

2001
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
    Cardiovascular drug reviews, 2001,Winter, Volume: 19, Issue:4

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Angioplasty, Balloon, Coronary; Animals; Arterial Occlusive Diseases; Cell Division; Cilostazol; Coronary Restenosis; Coronary Thrombosis; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Fibrinolytic Agents; Humans; Hypolipidemic Agents; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Vasodilator Agents

2001

Trials

32 trial(s) available for adenosine and Stroke

ArticleYear
High-dose adenosine versus saline-induced cardioplegic arrest in coronary artery bypass grafting: A randomized double-blind clinical feasibility trial.
    Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society, 2022, Volume: 111, Issue:3

    Topics: Adenosine; Coronary Artery Bypass; Feasibility Studies; Heart Arrest; Heart Arrest, Induced; Humans; Nucleosides; Potassium; Stroke

2022
Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design.
    International journal of stroke : official journal of the International Stroke Society, 2017, Volume: 12, Issue:3

    Topics: Adenosine; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Heterozygote; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Research Design; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2017
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
    Stroke, 2017, Volume: 48, Issue:9

    Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticagrelor; Treatment Outcome

2017
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.
    Journal of the American College of Cardiology, 2017, Aug-01, Volume: 70, Issue:5

    Topics: Adenosine; Aged; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Time Factors

2017
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2018, Volume: 55, Issue:1

    Topics: Adenosine; Aged; Clopidogrel; Female; Hospitalization; Humans; Hypertension; Incidence; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome; Vascular Surgical Procedures

2018
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
    Stroke, 2013, Volume: 44, Issue:5

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial.
    American heart journal, 2013, Volume: 166, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Survival Analysis; Ticagrelor; Treatment Outcome

2013
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REA
    Journal of cardiovascular translational research, 2014, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Coronary Thrombosis; Drug Administration Schedule; Fibrinolytic Agents; Germany; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Stents; Stroke; Thiophenes; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome

2014
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
    European heart journal, 2014, Jun-14, Volume: 35, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Sex Factors; Stents; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2014
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    European journal of preventive cardiology, 2015, Volume: 22, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome

2015
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome

2015
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Journal of cardiovascular pharmacology, 2016, Volume: 68, Issue:2

    Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome

2016
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
    Journal of the American College of Cardiology, 2016, Jun-14, Volume: 67, Issue:23

    Topics: Adenosine; Aged; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor

2016
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
    Journal of the American College of Cardiology, 2016, Jun-14, Volume: 67, Issue:23

    Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Lower Extremity; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor; Vascular Grafting

2016
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
    The New England journal of medicine, 2016, Jul-07, Volume: 375, Issue:1

    Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor

2016
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
    American heart journal, 2016, Volume: 175

    Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    American heart journal, 2016, Volume: 177

    Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine

2016
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
    American heart journal, 2016, Volume: 177

    Topics: Adenosine; Clopidogrel; Cost Sharing; Drug Costs; Financial Support; Health Care Costs; Health Expenditures; Humans; Logistic Models; Medication Adherence; Mortality; Multivariate Analysis; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2016
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.
    JAMA cardiology, 2016, Jul-01, Volume: 1, Issue:4

    Topics: Adenosine; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Quality of Life; Secondary Prevention; Stroke; Ticagrelor

2016
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    American heart journal, 2016, Volume: 178

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors

2016
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
    Circulation, 2016, Sep-20, Volume: 134, Issue:12

    Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Secondary Prevention; Stroke; Ticagrelor

2016
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
    American heart journal, 2016, Volume: 179

    Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome

2016
Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
    Stroke, 2017, Volume: 48, Issue:1

    Topics: Adenosine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Aspirin; Cohort Studies; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome

2017
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.
    The Lancet. Neurology, 2017, Volume: 16, Issue:4

    Topics: Adenosine; Adult; Aged; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolytic Agents; Humans; International Cooperation; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Stroke; Ticagrelor; Treatment Outcome

2017
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine

2009
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Circulation, 2011, Aug-02, Volume: 124, Issue:5

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States

2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2011
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
    Circulation, 2012, Feb-28, Volume: 125, Issue:8

    Topics: Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
    Circulation, 2012, Jun-12, Volume: 125, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine

2012
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
    European heart journal, 2013, Volume: 34, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2013
Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenosine; Aged; Aminoimidazole Carboxamide; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Perioperative Period; Reperfusion Injury; Ribonucleosides; Stroke; Ventricular Dysfunction, Left

2012
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Severity of Illness Index; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome

2013

Other Studies

47 other study(ies) available for adenosine and Stroke

ArticleYear
Neuroprotective Effects of a Cardioplegic Combination (Adenosine, Lidocaine, and Magnesium) in an Ischemic Stroke Model.
    Molecular neurobiology, 2022, Volume: 59, Issue:11

    Topics: Adenosine; Animals; Cardioplegic Solutions; Cobalt; Disease Models, Animal; Glucose; Humans; Ischemic Stroke; Lidocaine; Magnesium; Neuroblastoma; Neuroprotective Agents; Oxygen; Rats; Stroke

2022
Serum adenosine deaminase activity and acute cerebral infarction: a retrospective case-control study based on 7913 participants.
    Aging, 2022, 10-17, Volume: 14, Issue:21

    Topics: Adenosine; Adenosine Deaminase; Brain Ischemia; Case-Control Studies; Cerebral Infarction; Humans; Retrospective Studies; Stroke

2022
FTO-dependent m
    Nature communications, 2023, 01-30, Volume: 14, Issue:1

    Topics: Adenosine; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Endothelial Cells; Infarction; Male; Mice; Phosphatidate Phosphatase; RNA, Circular; RNA, Messenger; Stroke

2023
Adenosine receptor A1 enhanced mitochondrial biogenesis and exerted neuroprotection after cerebral ischemia through PGC-1α.
    Experimental brain research, 2023, Volume: 241, Issue:6

    Topics: Adenosine; Animals; Brain Ischemia; Ischemic Stroke; Mice; Neuroprotection; Organelle Biogenesis; Receptors, Purinergic P1; Stroke

2023
Adenosinergic System Involvement in Ischemic Stroke Patients' Lymphocytes.
    Cells, 2020, 04-25, Volume: 9, Issue:5

    Topics: 5'-Nucleotidase; Adenosine; Aged; Aged, 80 and over; Antigens, CD; Apyrase; Brain Ischemia; Female; GPI-Linked Proteins; Humans; Ischemic Stroke; Lymphocytes; Male; Membrane Proteins; Phosphoproteins; Receptors, Purinergic P1; Stroke

2020
Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk.
    Clinical and translational science, 2021, Volume: 14, Issue:1

    Topics: Adenosine; Aged; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Heart Disease Risk Factors; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Registries; Risk Assessment; Stroke

2021
Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™.
    Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2017, Volume: 23, Issue:3

    Topics: Adenosine; Aged; Aspirin; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine

2017
[Contemporary use of ticagrelor in patients with acute coronary syndrome after discharge].
    Zhonghua yi xue za zhi, 2017, Apr-18, Volume: 97, Issue:15

    Topics: Acute Coronary Syndrome; Adenosine; Humans; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine

2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    American heart journal, 2017, Volume: 186

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Streptokinase; Stroke; Ticagrelor; Ticlopidine; Tissue Plasminogen Activator

2017
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome
    Circulation, 2017, Sep-05, Volume: 136, Issue:10

    Topics: Adenosine; Aged; Aspirin; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Purinergic P2Y Receptor Antagonists; Risk; Stroke; Ticagrelor; Treatment Outcome

2017
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
    Coronary artery disease, 2018, Volume: 29, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Greece; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Stroke; Ticagrelor; Ticlopidine

2018
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Hemorrhage; Heterozygote; Homozygote; Humans; Hypertension; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2018
tiRNAs as a novel biomarker for cell damage assessment in in vitro ischemia-reperfusion model in rat neuronal PC12 cells.
    Brain research, 2019, 07-01, Volume: 1714

    Topics: Adenosine; Animals; Biomarkers; Cell Survival; Glucose; Hypoxia; Ischemia; Neurons; Oxygen; PC12 Cells; Rats; Reperfusion Injury; Ribonuclease, Pancreatic; RNA, Transfer; Stress, Physiological; Stroke

2019
Examination of the associations between m
    Hypertension research : official journal of the Japanese Society of Hypertension, 2019, Volume: 42, Issue:10

    Topics: Adenosine; Blood Pressure; Coronary Artery Disease; Genome-Wide Association Study; Homeodomain Proteins; Humans; Polymorphism, Single Nucleotide; Qb-SNARE Proteins; Stroke

2019
Delayed administration of the nucleic acid analog 2Cl-C.OXT-A attenuates brain damage and enhances functional recovery after ischemic stroke.
    Brain research, 2013, Apr-19, Volume: 1506

    Topics: Adenosine; Animals; Blotting, Western; Cerebrovascular Circulation; Disease Models, Animal; Immunohistochemistry; In Situ Nick-End Labeling; Male; MAP Kinase Signaling System; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Recovery of Function; Stroke

2013
Letter by Serebruany and DiNicolantonio regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
    Stroke, 2013, Volume: 44, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis

2013
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
    Stroke, 2013, Volume: 44, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis

2013
Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014, Volume: 34, Issue:6

    Topics: Adenosine; Animals; Brain Ischemia; Chemokine CCL2; Ectodysplasins; Fibrinolytic Agents; Interleukin-1; Mice; Mice, Transgenic; Microglia; Nerve Tissue Proteins; Nitric Oxide Synthase Type II; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Stroke; Ticagrelor; Time Factors

2014
Spreading depolarization-induced adenosine accumulation reflects metabolic status in vitro and in vivo.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014, Volume: 34, Issue:11

    Topics: Adenosine; Animals; Biomarkers; Brain; Brain Ischemia; Cortical Spreading Depression; Mice; Stroke

2014
Inefficacy of platelet transfusion to reverse ticagrelor.
    The New England journal of medicine, 2015, Jan-08, Volume: 372, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Antidotes; Fatal Outcome; Humans; Male; Platelet Count; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor

2015
The use of nanotechnology to improve the neuroprotective effects of adenosine in stroke and spinal cord injury.
    Neurosurgery, 2015, Volume: 76, Issue:4

    Topics: Adenosine; Animals; Drug Delivery Systems; Humans; Male; Nanoparticles; Nanotechnology; Neuroprotective Agents; Spinal Cord Injuries; Squalene; Stroke

2015
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
    Clinical cardiology, 2016, Volume: 39, Issue:1

    Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2016
Symptomatic intracerebral and systemic hemorrhage after stroke thrombolysis in patients taking ticagrelor.
    International journal of stroke : official journal of the International Stroke Society, 2016, Volume: 11, Issue:6

    Topics: Adenosine; Aged; Female; Fibrinolytic Agents; Hemorrhage; Humans; Stroke; Thrombolytic Therapy; Ticagrelor; Tissue Plasminogen Activator

2016
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine

2016
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
    BMJ (Clinical research ed.), 2016, Jun-22, Volume: 353

    Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Drug Therapy, Combination; Electronic Health Records; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticagrelor; Time Factors

2016
In acute stroke or TIA, ticagrelor did not differ from aspirin for a composite of stroke, MI, or death at 90 days.
    Annals of internal medicine, 2016, 08-16, Volume: 165, Issue:4

    Topics: Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke; Ticagrelor

2016
Bone: Antiplatelet agent promotes bone formation.
    Nature reviews. Endocrinology, 2016, Volume: 12, Issue:11

    Topics: Adenosine; Bone and Bones; Humans; Osteogenesis; Platelet Aggregation Inhibitors; Stroke

2016
Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)".
    Stroke, 2017, Volume: 48, Issue:4

    Topics: Adenosine; Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine

2017
Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcom
    Stroke, 2017, Volume: 48, Issue:4

    Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine

2017
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
    Hamostaseologie, 2009, Volume: 29, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor

2009
The PLATO trial: do you believe in magic?
    European heart journal, 2010, Volume: 31, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intracranial Hemorrhages; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2010
Ticagrelor versus clopidogrel in acute coronary syndromes.
    The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine

2009
Anti-metabolic syndrome effects of adenosine ingestion in stroke-prone spontaneously hypertensive rats fed a high-fat diet.
    The British journal of nutrition, 2010, Volume: 104, Issue:1

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenosine; Adiponectin; Adipose Tissue; Animals; Antioxidants; Blood Glucose; Cardiovascular Agents; Deoxyguanosine; Dietary Fats; Enzymes; Gene Expression; Gene Expression Regulation; Hypertension; Insulin; Kidney; Lipids; Liver; Male; Metabolic Syndrome; Nitric Oxide; Rats; Rats, Inbred SHR; Receptors, Adiponectin; RNA, Messenger; Stroke

2010
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2012, Volume: 13, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome

2012
Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review.
    American journal of therapeutics, 2012, Volume: 19, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Humans; Multicenter Studies as Topic; Peripheral Arterial Disease; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor

2012
Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke.
    Circulation, 2012, Jun-12, Volume: 125, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticagrelor; Ticlopidine

2012
Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study.
    JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:6

    Topics: Acetylcholine; Adenosine; Adult; Blood Flow Velocity; Coronary Angiography; Coronary Circulation; Coronary Vessels; Female; Heart Failure; Hospitalization; Humans; Laser-Doppler Flowmetry; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Nitroglycerin; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Stroke; United States; Vasodilator Agents

2012
Ticagrelor FDA approval issues revisited.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration

2012
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor

2012
Letter by Fort and Plachetka regarding article, "association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO".
    Circulation, 2012, Sep-11, Volume: 126, Issue:11

    Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stroke; Ticlopidine

2012
Intermediate-term prognostic value of reversible perfusion deficit diagnosed by adenosine CMR: a prospective follow-up study in a consecutive patient population.
    JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:1

    Topics: Adenosine; Aged; Angina, Stable; Chi-Square Distribution; Contrast Media; Coronary Circulation; Female; Follow-Up Studies; Gadolinium DTPA; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Time Factors; Vasodilator Agents

2013
The neurovascular dysfunction induced by angiotensin II in the mouse neocortex is sexually dimorphic.
    American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:1

    Topics: Acetylcholine; Adenosine; Angiotensin II; Animals; Blood Flow Velocity; Blood Pressure; Cerebrovascular Circulation; Disease Models, Animal; Disease Susceptibility; Estradiol; Estrogen Replacement Therapy; Female; Hypertension; Infusion Pumps, Implantable; Laser-Doppler Flowmetry; Male; Mice; Mice, Inbred C57BL; Neocortex; Ovariectomy; Reflex; Sex Factors; Stroke; Time Factors; Vasodilator Agents; Vibrissae

2008
Sex differences in adenosine deaminase activity of stroke patients.
    Clinical chemistry and laboratory medicine, 2008, Volume: 46, Issue:4

    Topics: Adenosine; Adenosine Deaminase; Aged; Blood Chemical Analysis; Female; Humans; Inosine; Ischemia; Male; Middle Aged; Risk Factors; Sex Characteristics; Sex Factors; Stroke; Time Factors

2008
Unravelling adenosine's effects on stroke.
    Molecular medicine today, 2000, Volume: 6, Issue:2

    Topics: Adenosine; Animals; Brain Ischemia; Gene Deletion; Glutamic Acid; Humans; Mice; Mice, Knockout; Neurodegenerative Diseases; Neuroprotective Agents; Phenotype; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A2A; Receptors, Purinergic P1; Stroke

2000
Increase in plasma adenosine during brain ischemia in man: a study during transient ischemic attacks, and stroke.
    Brain research bulletin, 2000, Mar-01, Volume: 51, Issue:4

    Topics: Adenosine; Aged; Female; Humans; Ischemic Attack, Transient; Male; Stroke

2000
Aggrenox and stress testing.
    Circulation, 2001, Feb-27, Volume: 103, Issue:8

    Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Ischemia; Platelet Aggregation Inhibitors; Stroke; Vasodilator Agents

2001
Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke.
    Annals of the New York Academy of Sciences, 2001, Volume: 939

    Topics: Adenosine; Animals; Brain; Brain Ischemia; Male; Mice; Neurons; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Receptors, Purinergic P1; Stroke

2001